$CGTX
COGNITION THERAPEUTICS INC

2022 Q4 Form 10-Q Financial Statement

#000155837022017604 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.860M $4.357M
YoY Change -54.13% 181.46%
% of Gross Profit
Research & Development $6.440M $8.268M
YoY Change 15.56% 124.98%
% of Gross Profit
Depreciation & Amortization $23.00K $22.00K
YoY Change 0.0% -4.35%
% of Gross Profit
Operating Expenses $9.300M $12.63M
YoY Change -21.24% 141.72%
Operating Profit -$12.63M
YoY Change 141.72%
Interest Expense -$10.00K -$2.000K
YoY Change -1100.0%
% of Operating Profit
Other Income/Expense, Net $4.128M $6.000M
YoY Change -7.61% 183.96%
Pretax Income -$5.182M -$6.625M
YoY Change -29.39% 113.02%
Income Tax
% Of Pretax Income
Net Earnings -$5.182M -$6.625M
YoY Change -29.39% 113.02%
Net Earnings / Revenue
Basic Earnings Per Share -$0.29
Diluted Earnings Per Share -$0.20 -$0.29
COMMON SHARES
Basic Shares Outstanding 23.97M 22.71M
Diluted Shares Outstanding 23.02M

Balance Sheet

Concept 2022 Q4 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $41.56M $46.61M
YoY Change -24.05% 460.89%
Cash & Equivalents $41.56M $46.61M
Short-Term Investments
Other Short-Term Assets $2.413M $1.794M
YoY Change 21836.36% 17840.0%
Inventory
Prepaid Expenses $2.413M $1.794M
Receivables
Other Receivables $2.000K
Total Short-Term Assets $47.65M $50.93M
YoY Change -19.23% 407.39%
LONG-TERM ASSETS
Property, Plant & Equipment $233.0K $246.0K
YoY Change 60.69% 74.47%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.732M $1.688M
YoY Change -47.41%
Total Long-Term Assets $2.778M $2.625M
YoY Change 1815.86% -21.67%
TOTAL ASSETS
Total Short-Term Assets $47.65M $50.93M
Total Long-Term Assets $2.778M $2.625M
Total Assets $50.43M $53.56M
YoY Change -14.73% 300.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.216M $8.087M
YoY Change -22.84% 191.42%
Accrued Expenses $2.094M $2.314M
YoY Change 19.59% 212.7%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $7.795M $12.12M
YoY Change -0.88% 173.62%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.686M $1.518M
YoY Change -86.1%
Total Long-Term Liabilities $1.686M $1.518M
YoY Change -86.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.795M $12.12M
Total Long-Term Liabilities $1.686M $1.518M
Total Liabilities $10.18M $14.24M
YoY Change 29.4% -7.23%
SHAREHOLDERS EQUITY
Retained Earnings -$115.4M -$110.2M
YoY Change 22.76% 27.18%
Common Stock $29.00K $24.00K
YoY Change 31.82% 2300.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $40.25M $39.32M
YoY Change
Total Liabilities & Shareholders Equity $50.43M $53.56M
YoY Change -14.73% 300.01%

Cashflow Statement

Concept 2022 Q4 2022 Q3
OPERATING ACTIVITIES
Net Income -$5.182M -$6.625M
YoY Change -29.39% 113.02%
Depreciation, Depletion And Amortization $23.00K $22.00K
YoY Change 0.0% -4.35%
Cash From Operating Activities -$10.18M -$4.000K
YoY Change -10183.17% -99.8%
INVESTING ACTIVITIES
Capital Expenditures $10.00K -$23.00K
YoY Change -137.04%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$10.00K -$23.00K
YoY Change -62.96%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 5.142M 869.0K
YoY Change -88.91% -190.43%
NET CHANGE
Cash From Operating Activities -10.18M -4.000K
Cash From Investing Activities -10.00K -23.00K
Cash From Financing Activities 5.142M 869.0K
Net Change In Cash -5.052M 842.0K
YoY Change -110.88% -127.96%
FREE CASH FLOW
Cash From Operating Activities -$10.18M -$4.000K
Capital Expenditures $10.00K -$23.00K
Free Cash Flow -$10.19M $19.00K
YoY Change -8064.06% -100.93%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-14.87
CY2021Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.3092
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.29
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22230032
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23969497
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-40886
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
23024026
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
611680
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
22684309
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
585320
dei Entity Central Index Key
EntityCentralIndexKey
0001455365
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.12
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
dei Entity Registrant Name
EntityRegistrantName
Cognition Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
13-4365359
dei Entity Address Address Line1
EntityAddressAddressLine1
2500 Westchester Ave
dei Entity Address City Or Town
EntityAddressCityOrTown
Purchase
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10577
dei City Area Code
CityAreaCode
412
dei Local Phone Number
LocalPhoneNumber
481-2210
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001 per share
dei Trading Symbol
TradingSymbol
CGTX
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
23971042
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46610000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
54721000
CY2022Q3 us-gaap Grants Receivable Current
GrantsReceivableCurrent
2526000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
1799000
CY2022Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1794000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
2005000
CY2022Q3 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
2000
CY2021Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
467000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
50932000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
58992000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
246000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
145000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
691000
CY2022Q3 us-gaap Other Assets
OtherAssets
1688000
CY2022Q3 us-gaap Assets
Assets
53557000
CY2021Q4 us-gaap Assets
Assets
59137000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
8087000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4168000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2314000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1751000
CY2022Q3 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
1601000
CY2021Q4 cgtx Deferred Grant Income Current
DeferredGrantIncomeCurrent
753000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
114000
CY2021Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1192000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
12116000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7864000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
603000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1518000
CY2022Q3 us-gaap Liabilities
Liabilities
14237000
CY2021Q4 us-gaap Liabilities
Liabilities
7864000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23969497
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22230032
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
24000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
22000
CY2022Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
149716000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
145453000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-110219000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-94004000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-201000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-198000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
39320000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
51273000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
53557000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
59137000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8268000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3675000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
23884000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12999000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4357000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1548000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10367000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3791000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
12625000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
5223000
us-gaap Operating Expenses
OperatingExpenses
34251000
us-gaap Operating Expenses
OperatingExpenses
16790000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12625000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5223000
us-gaap Operating Income Loss
OperatingIncomeLoss
-34251000
us-gaap Operating Income Loss
OperatingIncomeLoss
-16790000
CY2022Q3 cgtx Grant Income
GrantIncome
5947000
CY2021Q3 cgtx Grant Income
GrantIncome
3037000
cgtx Grant Income
GrantIncome
18236000
cgtx Grant Income
GrantIncome
12375000
cgtx Fair Value Adjustment Of Derivative Liability
FairValueAdjustmentOfDerivativeLiability
2209000
CY2021Q3 cgtx Fair Value Adjustment Of Simple Agreements For Future Equity
FairValueAdjustmentOfSimpleAgreementsForFutureEquity
-932000
cgtx Fair Value Adjustment Of Simple Agreements For Future Equity
FairValueAdjustmentOfSimpleAgreementsForFutureEquity
-1976000
CY2022Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
55000
CY2021Q3 us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
8000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-182000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
256000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
443000
CY2022Q3 us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-2000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-18000
us-gaap Interest Income Expense Net
InterestIncomeExpenseNet
-894000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
6000000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2113000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
18036000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
12413000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6625000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3110000
us-gaap Net Income Loss
NetIncomeLoss
-16215000
us-gaap Net Income Loss
NetIncomeLoss
-4377000
CY2021Q3 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
1859000
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
4326000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-6625000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4969000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16215000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8703000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1000
CY2021Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-3000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-9000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6626000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3113000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16218000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4386000
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.29
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.71
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-14.87
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
23024026
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
611680
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
22684309
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
585320
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
51273000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
303000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1001000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
1000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-3838000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
48740000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
22000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
892000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5752000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
43899000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1270000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
777000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-6625000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
39320000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-68184000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
14000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
98000
CY2021Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-5000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
223000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-67854000
CY2021Q2 cgtx Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
34000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
94000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Equity Component Of Convertible Debt
AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt
-14465000
CY2021Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-1490000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-83682000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
72000
CY2021Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-3000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3110000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
-86718000
us-gaap Net Income Loss
NetIncomeLoss
-16215000
us-gaap Net Income Loss
NetIncomeLoss
-4377000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
60000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
70000
us-gaap Share Based Compensation
ShareBasedCompensation
2670000
us-gaap Share Based Compensation
ShareBasedCompensation
264000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
115000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
31000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
352000
cgtx Fair Value Adjustment Of Derivative Liability
FairValueAdjustmentOfDerivativeLiability
2209000
cgtx Fair Value Adjustment Of Simple Agreements For Future Equity
FairValueAdjustmentOfSimpleAgreementsForFutureEquity
-1976000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
443000
cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
727000
cgtx Increase Decrease In Grant Receivables
IncreaseDecreaseInGrantReceivables
283000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1477000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
18000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-465000
us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-264000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
3919000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-278000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
563000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
258000
cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
2366000
cgtx Increase Decrease In Deferred Grant Income Current
IncreaseDecreaseInDeferredGrantIncomeCurrent
661000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-88000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-8349000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3732000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
161000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-161000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1595000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
19000
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
1191000
cgtx Proceeds From Simple Agreements For Future Equity
ProceedsFromSimpleAgreementsForFutureEquity
8942000
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
34000
cgtx Payment Of Deferred Offering Costs
PaymentOfDeferredOfferingCosts
2155000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
404000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6840000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-5000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8111000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3121000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
54721000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5189000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
46610000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
8310000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
189000
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
29391000
cgtx Deferred Offering Costs Included In Accounts Payable
DeferredOfferingCostsIncludedInAccountsPayable
1055000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
46610000
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of other income and expenses during the reporting period. Actual results could differ from those estimates.</p>
CY2021Q4 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
46687000
CY2022Q3 cgtx Allowance For Credit Loss Grants Receivable Current
AllowanceForCreditLossGrantsReceivableCurrent
0
CY2022Q3 cgtx Grant Income
GrantIncome
5947000
cgtx Grant Income
GrantIncome
18236000
CY2021Q3 cgtx Grant Income
GrantIncome
3037000
cgtx Grant Income
GrantIncome
12375000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
884000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
167000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
717000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y6M
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:20.15pt;margin:0pt 0pt 12pt 0pt;">The Company’s financial instruments that are exposed to credit risks consist of cash and cash equivalents. The Company maintains its cash and cash equivalents in bank deposit accounts, which, at times, may exceed the federally insured limit. The Company has not experienced any losses in these accounts and does not believe it is exposed to any significant credit risk related to these funds.</p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Assets Fair Value Disclosure
AssetsFairValueDisclosure
42260000
CY2020Q4 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
2209000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
8942000
cgtx Fair Value Adjustment Of Derivative Liability
FairValueAdjustmentOfDerivativeLiability
2209000
CY2021Q3 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value
FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
10918000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1287000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1285000
CY2022Q3 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
178000
CY2021Q4 cgtx Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
250000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
815000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
216000
CY2022Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
34000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2314000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1751000
CY2022Q3 cgtx Operating Lease Assets
OperatingLeaseAssets
691000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
691000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
114000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
603000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
717000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
50000
us-gaap Operating Lease Cost
OperatingLeaseCost
149000
CY2022Q3 us-gaap Lease Cost
LeaseCost
50000
us-gaap Lease Cost
LeaseCost
149000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
34000
us-gaap Operating Lease Expense
OperatingLeaseExpense
116000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
41000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
166000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
167000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
169000
CY2022Q3 cgtx Lessee Operating Lease Liability To Be Paid After Year Three
LesseeOperatingLeaseLiabilityToBePaidAfterYearThree
341000
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.081
us-gaap Operating Lease Payments
OperatingLeasePayments
123000
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
838000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.9109
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.9272
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
1.0082
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1.0183
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0187
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0340
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0067
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0106
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5640438
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.19
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
12002000
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
449270
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.50
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1739465
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.92
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
616334
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
463
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
0.84
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3733446
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.32
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1652000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M12D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2163738
CY2022Q3 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
21000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.57
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1300000
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7M6D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.47
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.90
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.79
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
14000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
449270
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
67232
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodTotalGrantDateFairValue
121000
CY2022Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1371589
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
1739465
CY2022Q3 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
1018000
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
1308000
CY2021Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4996
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
25783
CY2021Q3 cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
3000
cgtx Share Based Compensation Arrangement By Share Based Payment Award Options Exercised In Period Total Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisedInPeriodTotalGrantDateFairValue
14000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
1596000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2717000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
26000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
140000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
777000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
72000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2670000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
264000
CY2022Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
7338000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y2M12D
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3733446
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
20375329

Files In Submission

Name View Source Status
0001558370-22-017604-index-headers.html Edgar Link pending
0001558370-22-017604-index.html Edgar Link pending
0001558370-22-017604.txt Edgar Link pending
0001558370-22-017604-xbrl.zip Edgar Link pending
cgtx-20220930.xsd Edgar Link pending
cgtx-20220930x10q.htm Edgar Link pending
cgtx-20220930xex31d1.htm Edgar Link pending
cgtx-20220930xex31d2.htm Edgar Link pending
cgtx-20220930xex32d1.htm Edgar Link pending
cgtx-20220930xex32d2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
cgtx-20220930_def.xml Edgar Link unprocessable
cgtx-20220930_lab.xml Edgar Link unprocessable
cgtx-20220930x10q_htm.xml Edgar Link completed
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
cgtx-20220930_cal.xml Edgar Link unprocessable
cgtx-20220930_pre.xml Edgar Link unprocessable